From: Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
Group
600
300
150
75
37.5
IC50
OCUM-2MD3
90.2 ± 1.7
81.1 ± 1.5
75.5 ± 2.9
65.3 ± 3.3
42.6 ± 1.6
44.5
OCUM-2MD3/L-OHP
94.5 ± 0.7*
85.0 ± 2.4*
79.4 ± 2.1*
67.7 ± 1.2*
50.9 ± 3.4*
36.8